Risedronate for Paget's disease of bone.
D000284:Administration, Oral; D000368:Aged; D001862:Bone Resorption / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000139:chemically induced; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004941:Esophagitis / Q000139:chemically induced; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010001:Osteitis Deformans / Q000188:drug therapy*; D000068296:Risedronic Acid
D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid